Kornimate/medical-research-clean huggingface dataset:
efficacy of two nasal products for decongestion and mucus fluidification

Conditions: Rhinitis

Summary: the main objective is to compare the effect of nasal washing on nasal discharge and nasal congestion during treatment after 3 days of use.

the main endpoint is a symptom score derived from the jackson scale: sum of 2 items relating to runny nose and nasal congestion (stuffy nose), with ratings of 0 to 3 for each (0: absent ; 1: mild; 2: moderate; 3: severe).

Eligibility criteria:
inclusion criteria: * person with an upper respiratory condition (cold, rhinitis, nasopharyngitis ...) with symptoms of nasal congestion and intense runny nose moderate to severe (jackson derived score ≥ 4) * ability of the patient (for adults) or their legal representative (for children) to follow the guidelines of the medical device * have given their written informed consent exclusion criteria: * patient with no cold symptoms, including no nasal congestion (chronic dry rhinitis...) * patient under treatment with cortisone derivative, mucolytic, or medication containing pseudoephedrine or related product acting on nasal congestion or having used such a product in the 3 days before inclusion * patient who used a nasal wash product in the 3 days before inclusion * patient allergic to seafood, or to any of the components of the products under study * vulnerable patient whose inclusion is not justified by the research objectives: woman pregnant, parturient, psychiatric patient, or adult subject to legal protection * patient participating or having participated in any other clinical study in the 30 days before the study.
tetracycline-derivatives for treatment of cerebral arteriovenous malformations and aneurysms

Conditions: Aneurysms; Arteriovenous Malformations

Summary: the purpose of this pilot study is to investigate the use of minocycline and doxycycline as medical therapy for inoperable or partially treated arteriovenous malformations (avms) and giant aneurysms.

arteriovenous malformations (avms) are a treatable cause of stroke in young adults. the processes by which avms and giant aneurysms grow in size and spontaneously bleed are unknown. the primary reason to treat avms and aneurysms is to guard against intracranial bleeding. this pilot study will examine the use of two common antibiotics-minocycline and doxycycline-as medical therapy for inoperable or partially treated avms and giant aneurysms. these drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases, that degrade tissue and thereby cause a reduction in the risk of spontaneous bleeding from avms or aneurysm-which is the main cause of stroke associated with these disorders. the enzymes can contribute to weaknesses in the wall of blood vessels and may increase the risk of the vessel wall rupturing and causing spontaneous bleeding. this trial also will show that taking minocycline and doxycycline over an extended period in this patient population is safe and well tolerated. results from this study could help plan future studies to benefit patients with abnormal blood vessels prone to bleeding in their brains.

Eligibility criteria:
inclusion criteria: * giant aneurysms or brain arteriovenous malformations (bavm) * female patients of child bearing age using effective birth control, males * creatinine no greater than 2.0 mg/dl * alt no greater than 2 times upper limit of control exclusion criteria: * unstable medical illness * contraindications to tetracycline * history of vestibular disease, (except benign positional vertigo) * prior tetracycline use within 2 mos of baseline visit. * history of noncompliance with treatment or other protocols * history of systemic lupus * patients not eligible for mri

Keywords: giant aneurysms arteriovenous malformations minocycline doxycycline bavm
laparoscopic versus robotic assisted laparoscopic sacrocolpopexy for vaginal prolapse

Conditions: Pelvic Organ Prolapse

Summary: the purpose of this study is to conduct a trial of robotic assisted versus traditional laparoscopic sacrocolpopexy in the treatment of patients with vaginal prolapse.

although laparoscopic sacrocolpopexy (lscasc) has been demonstrated to yield comparable success rates to abdominal sacrocolpopexy (93-99%) for the surgical treatment of pelvic organ prolapse, it has not been widely adopted due to the increased operating time and steep learning curves associated with laparoscopic suturing and knot-tying. for these reasons, robotic systems have been advocated for this technique. the objective of this study is to conduct a prospective single-blinded randomized controlled trial of robotic assisted versus traditional lscasc in the treatment of patients with apical vaginal prolapse stages ii-iv (prolapse from 1 cm proximal to the hymen to all points distal). this is a prospective single-blinded randomized controlled trial. robotic assisted lscasc will be performed using the da vinci surgical system (intuitive surgical inc., sunnyvale, ca, usa) in a similar manner as that described above for conventional laparoscopy. data points recorded during the procedure will include: operating room time of entry and exit, time from incision to closure and time taken for the suturing aspect of the case. from this information, the operating room costs and anesthesia costs, i.e., the amount that a provider must pay for goods or services, will be calculated. estimated blood loss, perioperative and post-operative complications, and number of days in the hospital will be studied as will cost-effectiveness and impact on hrqol

Eligibility criteria:
inclusion criteria: * women who are 21 years of age or greater * status post hysterectomy with apical vaginal prolapse popq stages ii-iv (prolapse from 1cm proximal to the hymen to all points distal) that desire laparoscopic surgical management. exclusion criteria: * patients that are not candidates for general anesthesia * inability to consent * history of prior sacralcolpopexy * suspicious adnexal masses or other factors that may indicate pelvic malignancy * history of pelvic inflammatory disease * morbid obesity (body mass index greater than or equal to 40) * history of prior or need for concomitant rectopexy with sigmoid resection.

Keywords: laparoscopy robot vaginal prolapse sacrocolpopexy sacral colpopexy
treatment of eosinophilic chronic rhinosinusitis utilizing betamethasone dipropionate nasal cream

Conditions: Chronic Rhinosinusitis (Diagnosis)

Summary: this is an open-label, single dose, pilot study, to assess the efficacy and safety of betamethasone dipropionate nasal cream 0.0644% (equivalent to 0.05% betamethasone) for the treatment of eosinophilic chronic rhinosinusitis (ecrs).

in this open-label study, a single dose of the corticosteroid betamethasone dipropionate nasal cream 0.0644% (equivalent to 0.05% betamethasone) will be administered under endoscopic guidance to the sinus mucosa of post-fess patients whose ecrs condition is suboptimal under the current standard of care. the safety and benefits of this treatment will be monitored by patient-reported symptoms and visualization of the sinus mucosa.

Eligibility criteria:
inclusion criteria: * adult patients with a clinically confirmed diagnosis of ecrs by a ent undergoing maximal medical therapy as part of their standard of care. * having undergone functional endoscopic sinus surgery at least 6 months prior to enrolment. * participants with an endoscopic bilateral nasal polyp score of ≤5 out of a maximum score of 8 * score \> 2 on disease severity visual analogue scale (vas) * a minimum body weight \>=40 kilograms (kg) at screening visit * gender: male or female (females of childbearing potential must use adequate birth control methods and not plan to get pregnant during the course of the study). * informed consent: willingness to give written informed consent and willingness to participate to and comply with the study. * age ≥18 but \<80 years. exclusion criteria: * subjects with known hypersensitivity or contraindications to betamethasone dipropionate, corticosteroids or topical anaesthesia. * subjects with sino-nasal abnormalities, disease or implanted devices that prevent application of the therapy. * previous enrolment in this study. * subjects currently required systemic corticosteroid use or receiving biologic therapy as part of their disease management plan or who meet the pbs criteria for severe lower airway disease. * subjects with history or current glaucoma or cataract or if they have abnormal iop at screening or pre-treatment (abnormal iop is defined as greater than 21 mm hg). * subjects with other conditions that could lead to elevated eosinophils such as hypereosinophilic syndromes, including churg-strauss syndrome, or eosinophilic esophagitis. * subjects with acute sinusitis. * subjects with known immunodeficiency. * subjects with diabetes (type 1). * subjects with cystic fibrosis. * pregnant subjects or subjects currently lactating as the effect on human pregnancy is unknown.

Keywords: eosinophilic chronic rhinosinusitis
a multicenter survey of the indications for esophagogastroduodenoscopy (egd)

Conditions: Digestive System Abnormalities; Endoscopy

Summary: esophagogastroduodenoscopy (egd) become more and more common in diagnosing gastroenterology diseases. the investigators want to find which symptoms can support for positive endoscopic findings through this multicenter study.

esophagogastroduodenoscopy (egd) become more and more common in diagnosing gastroenterology diseases. and there are indications for egd. here, investigators want to find which symptoms can strongly support for positive endoscopy findings. so, investigators design the study to record the symptoms in detail and diagnosis, and then analysis symptoms and the rate of endoscopic findings.

Eligibility criteria:
inclusion criteria: * all of the patients need esophagogastroduodenoscopic procedures exclusion criteria: * patients whose parents reject to provide information for study

Keywords: esophagogastroduodenoscopy paediatric
the study about the selection of time for retreatment of helicobacter pylori after eradication failure

Conditions: Helicobacter Pylori Infection

Summary: the patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

helicobacter pylori (hp) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. at present, due to the non-standard helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of hp eradication treatment failure is more and more common. however, there is still no conclusion on the most appropriate time for remedial treatment inpatients with hp eradication failure.

Eligibility criteria:
inclusion criteria: * patients aged 18-70 with h. pylori infection. * patients with previous helicobacter pylori eradication. exclusion criteria: * patients treated with h2-receptor antagonist, ppi, bismuth and antibioticsin the previous 4 weeks. * patients with gastrectomy, acute gi bleeding and advanced gastric cancer. * patients with known or suspected allergy to study medications. * currently pregnant or lactating. * inability to provide informed consent and other situations that couldinterfere with the examination or therapeutic protocol.

Keywords: helicobacter pylori re-eradication time remedial treatment
dietary protein in the very-low-birth-weight infant

Conditions: Prematurity

Summary: in this randomized study the investigators aim to compare the growth of very-low-birth-weight (vlbw) infants fed either a high protein or a standard protein preterm infant formula. babies will be fed the assigned formula between the time they achieve full enteral feeds and hospital discharge, for a minimum of 3 weeks. the weight gain (g/d) will be measured and compared between groups. feeding tolerance, protein-energy status and body composition between the study groups will also be analysed. after discharge, babies will be fed a post-discharge preterm infant formula (pdf) between hospital discharge and 3 m corrected age.


Eligibility criteria:
inclusion criteria: * gestational age \<32 w, determined by maternal dates, fetal ultrasound, dubowitz/ballard examination or a combination thereof * birth weight ≤1500 g * tolerating an enteral intake of ≥100 ml/kg/d for ≥ 24 h * subject is anticipated to receive the study formula for ≥ 3 consecutive weeks after fef have been achieved * in infants fed human milk, formula is anticipated to provide 50% or more of total energy intake, calculated on a weekly basis and based on the assumption that human milk has an energy density of 67 kcal/dl * written informed consent has been obtained from the legal representative exclusion criteria: * cardiac failure requiring fluid restriction with diuretic therapy for ≥ 3 consecutive days * peri-/intra-ventricular haemorrhage (grade 3-4) determined using cranial ultrasonography * renal disease: by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased bun and creatinine * sepsis: defined by symptoms requiring antibiotic therapy and confirmed by a positive blood culture * necrotizing enterocolitis: defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - bell stage 2; air in the biliary tract or free air in the peritoneum - bell stage 3) * hepatic dysfunction: defined by jaundice (direct bilirubin \>1.0 mg/dl) which is associated with one or more abnormal liver function tests (ast, alt or ggt) * lung disease, severe enough to require steroid therapy. * small size for gestational age (sga) - body weight ≤ 5th percentile for that gestational age. * participation in another clinical trial that may affect outcomes of this study

Keywords: prematurity enteral feeding proteins formula
symbicort single inhaler therapy vs conventional best practice for the treatment of persistent asthma in adults

Conditions: Asthma, Bronchial

Summary: this study is intended to extend the knowledge of symbicort single inhaler therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. the study will compare the symbicort single inhaler therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (gcs) treatment or who require and are already on treatment with a combination of inhaled and long-acting b2 agonists (laba).


Eligibility criteria:
inclusion criteria: * minimum of 3 months history of asthma, diagnosed according to the american thoracic society (ats) definition (9). * prescribed inhaled gcs at a dose of 400μg/day of budesonide (or equivalents)and within the approved label for the relevant drug during the last 3 months prior to visit 1. * either daily maintenance treatment with both inhaled gcs and laba or daily treatment with inhaled gcs alone (i.e. without laba) * a history of suboptimal asthma control the month prior to enrolment as judged by the investigator * use of ≥3 inhalations of as needed medication for symptom relief during the last 7 days before enrolment exclusion criteria: * previous treatment with symbicort single inhaler; * use of any b-blocking agent, including eye-drops and oral gcs as maintenance treatment. * known or suspected hypersensitivity to study therapy or excipients. * a history of smoking ≥ 10 pack years. * asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at visit 1.
evaluation of the impact of mobile phone messages on art and pmtct adherence in mozambique

Conditions: HIV-positive

Summary: mobile phone sms are increasingly used to promote positive health behaviour with an aim to improve health outcomes. however, robust data on the efficacy of sms on health seeking behaviour and patient outcomes in resource-limited settings is sparse. the smsaude study aims to assess whether regular sms-reminders improve retention on antiretroviral therapy (art) and prevention of mother to child transmission of hiv (pmtct) programmes in mozambique.

smsaúde is a multisite randomised clinical trial of hiv-infected adults on art and hiv-infected pregnant women in six clinics in maputo province, mozambique. eligibility criteria include: currently residing in the province; no plans to move for 12+ months; have own cell-phone; literate; 8-28 weeks pregnant (pmtct cohort); on first line art and on art for \>15 days (art cohort). patients were interviewed for eligibility, and then randomized (1:1). sms reminders are sent to the intervention group using software that picks up the patient's next appointment from the electronic patient database. primary outcomes tested were improved retention in art care and uptake of all pmtct services.

Eligibility criteria:
inclusion criteria: * on art for \>15 days (for art only) * live in province and plan to stay for 12+ months * have cell phone * literate for pmtct (in addition to above criteria): - pregnant between 8-28 weeks exclusion criteria: -

Keywords: mhealth mobile health sms sms reminders art retention in care pmtct pmtct cascade retention in care
"herzcheck" - detection of early heart failure using telemedicine in structurally weak regions

Conditions: Heart Failure with Preserved Ejection Fraction

Summary: this study is intended to provide a basis for decision-making for the improved medical care of patients with asymptomatic heart failure, especially in structurally weak regions.

the aim of the study is the early detection of asymptomatic heart failure with a quality-assured cardiac screening mri in the population in structurally weak regions and especially in patients with risk factors for the occurrence of heart failure. the diagnosis is followed by early initiation of appropriate therapeutic measures to improve the prognosis of the affected patients, avoid hospitalisations and save therapy costs, and is combined with recommended measures to minimise risk factors for the development of heart failure. the project includes a prospective, monocentric, randomised controlled clinical trial with blinded assessment of the endpoint (probe design). within the scope of the study, 4,509 patients aged between 40 and 69 years who have characteristic risk factors for the development of heart failure were examined using a mobile cardiac screening mri in the federal states of brandenburg and mecklenburg-western pomerania within germany.

Eligibility criteria:
inclusion criteria: * smoking * hypercholesterolaemia * arterial hypertension * obesity * chronic diabetes mellitus * chronic kidney disease * health insurance exclusion criteria: * previously diagnosed heart failure * mri-exclusion criteria

Keywords: prevention heart failure hfpef asymptomatic cardiology rural region germany cmr cardiac magnetic resonance hfref diastolic dysfunction strain telemedicine
the efficacy of sch1 in the treatment of acute infectious conjunctivitis

Conditions: Acute Infectious Conjunctivitis (Disorder)

Summary: the objective of this study is to evaluate the efficacy of sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

this is a phase ii single-center, double-masked, placebo controlled, randomized study of sch1 for the treatment of infectious conjunctivitis. approximately 30 subjects will be enrolled, who will be randomized in a 1:1 ratio between sch1and placebo. subjects will be assessed at day 1, day 3, and day 5 for efficacy and safety.

Eligibility criteria:
inclusion criteria: * conjunctivitis (as defined below) within 72 hours of initial ocular symptoms. * at least 18 years of age. * subjects capable of understanding the purpose and risks of the study, and able to give informed consent. * conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates. * a three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates. * all patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates. * patients will require a rating of 1 (mild) for bulbar conjunctival injection. exclusion criteria: * conjunctivitis greater than 72 hours after initial ocular symptoms * corneal ulcer, endophthalmitis, or any other confounding infection of the eye * patients taking topical anti-inflammatory medications on a chronic basis * known steroid glaucoma responders * active herpes ocular infection * pregnant women * known allergy to chlorhexidine

Keywords: conjunctivitis eye
identification of the molecular and/or pathophysiological bases of developmental diseases

Conditions: Developmental Anomalies

Summary: developmental diseases include more than 3000 diseases and can associate organ malformation, dysmorphism, development disorders and/or intellectual deficiency. even though the considerable effort in the search for genes in the last 20 years has led to the identification of thousands of genes associated with mendelian diseases, half of the individuals with severe development anomalies remain without a genetic diagnosis. it is important to pursue the ambition to contribute to the goal fixed by europe, namely the identification of the large majority of genes responsible for rare diseases with development anomalies, and to be able to provide genetic counselling to patients and their families. in the past, scientific research to discover genes required a large number of families and individuals and was slow and expensive to carry out. today, this approach has been facilitated by next generation sequencing.


Eligibility criteria:
inclusion criteria: * patients (foetus/children and adults) with development anomalies whose molecular bases are unknown, or for which the pathophysiological mechanism is poorly understood * consent of the patient or his/her legal representative * suitable level of understanding exclusion criteria: * patients without national health insurance cover
bilateral, masked comparison of peg-400 based artificial tear vs. systane for dry eye signs, symptoms & refractive regression associated with myopic laser in situ keratomilieusis (lasik).

Conditions: Dry Eye Syndromes

Summary: this study will evaluate and compare 2 artificial tears in their ability to reduce post lasik dry eye signs and symptoms. the secondary endpoint of this study is to evaluate refractive regression in these patients. the 'refractive outcome' data point will be defined as the difference between the post-op spherical equivalent (se) and the pre-op targeted se.


Eligibility criteria:
inclusion criteria: * patients ranging from normal to mild dry eye per physician assessment * bcva of 20/20 * moderate to high myopia (-3 d to -10d of sphere) * patients who are scheduled to under go myopic bilateral lasik with visx laser exclusion criteria: * patients currently using topical cyclosporine * patients currently using systane * patients currently using an oil-based artificial tear such as soothe or endura * any post-op epithelial defects or flap complications requiring further procedures (relifting, scraping, stretching etc.) * dlk greater than stage 1 or infectious keratitis post-operatively * any uncontrolled systemic disease that may confound the results of this trial (diabetes, lupus, rheumatoid arthritis etc.) * anisometropia greater than 1d

Keywords: dry eye signs and symptoms refractive regression